Finkelstein Thompson LLP Announces Investigation Of Clarient, Inc.
Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Clarient, Inc. (“Clarient” or the “Company”) (Nasdaq: CLRT) concerning the Company’s receipt of an offer to purchase all outstanding common shares of the Company for $5 per share and each outstanding preferred share for $20 by GE Healthcare, Inc. The proposed offer is valued at approximately $580 million and is expected to close in late 2010 or early 2011.
The investigation is focused on the potential unfairness of the transaction price to Clarient shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among Clarient Board members. Stockholders holding approximately 47% of Clarient’s current outstanding voting stock have agreed to tender their shares in the proposed offer, about 35% of which is held by insiders and major shareholders of the Company. Additionally, according to Yahoo! Finance, at least one analyst has set a target price of $6 for Clarient stock.
If you are interested in discussing your rights as a Clarient shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at firstname.lastname@example.org.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV